MiCo BioMed Balance Sheet Health
Financial Health criteria checks 3/6
MiCo BioMed has a total shareholder equity of ₩31.2B and total debt of ₩5.7B, which brings its debt-to-equity ratio to 18.2%. Its total assets and total liabilities are ₩51.0B and ₩19.9B respectively.
Key information
18.2%
Debt to equity ratio
₩5.66b
Debt
Interest coverage ratio | n/a |
Cash | ₩10.23b |
Equity | ₩31.16b |
Total liabilities | ₩19.85b |
Total assets | ₩51.01b |
Financial Position Analysis
Short Term Liabilities: A214610's short term assets (₩33.6B) exceed its short term liabilities (₩14.6B).
Long Term Liabilities: A214610's short term assets (₩33.6B) exceed its long term liabilities (₩5.3B).
Debt to Equity History and Analysis
Debt Level: A214610 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A214610's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A214610 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A214610 has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.7% each year.